PART I . Overview Lisata Therapeutics, Inc. (together with its subsidiaries, the Company) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other serious diseases. Our investigational product, certepetide (formerly known as LSTA1 or CEND-1), is designed to activate a novel uptake pathway (the C-end rule active transport mechanism) that allows co-administered or tethered (i.e., mo...
Q2 FY2026 — expected 2026-08-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-12 | 2025-12-31 | 0000320017-26-000023 | EDGAR | 80K words |
| 2025-02-27 | 2024-12-31 | 0000320017-25-000011 | EDGAR | — |
| 2024-02-29 | 2023-12-31 | 0000320017-24-000007 | EDGAR | — |
| 2023-03-30 | 2022-12-31 | 0000320017-23-000011 | EDGAR | — |
| 2022-03-22 | 2021-12-31 | 0000320017-22-000016 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0000320017-21-000043 | EDGAR | — |
| 2020-03-05 | 2019-12-31 | 0000320017-20-000016 | EDGAR | — |
| 2019-03-14 | 2018-12-31 | 0000320017-19-000024 | EDGAR | — |
| 2018-03-22 | 2017-12-31 | 0000320017-18-000021 | EDGAR | — |
| 2017-03-17 | 2016-12-31 | 0000320017-17-000008 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0000320017-25-000070 | EDGAR | 21K words |
| 2025-08-07 | 2025-06-30 | 0000320017-25-000060 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0000320017-25-000030 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000320017-24-000058 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0000320017-24-000051 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000320017-24-000031 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0000320017-23-000063 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0000320017-23-000055 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0000320017-23-000028 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0000320017-22-000102 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0000320017-22-000057 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0000320017-22-000042 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-03 | 0001140361-26-013070 | EDGAR | 2K words |
| 2026-03-09 | 0000320017-26-000020 | EDGAR | — |
| 2026-02-27 | 0000320017-26-000012 | EDGAR | — |
| 2026-01-27 | 0000320017-26-000008 | EDGAR | — |
| 2026-01-21 | 0000320017-26-000006 | EDGAR | — |
| 2025-11-06 | 0000320017-25-000069 | EDGAR | — |
| 2025-10-14 | 0000320017-25-000066 | EDGAR | — |
| 2025-10-08 | 0000320017-25-000063 | EDGAR | — |
| 2025-08-07 | 0000320017-25-000059 | EDGAR | — |
| 2025-07-15 | 0000320017-25-000048 | EDGAR | — |
340 total filings indexed. 308 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000320017 |
| Ticker | LSTA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.lisata.com |
| Listed | 1999-03-01 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report